Citadel Advisors
ELOX

Citadel Advisors’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

Citadel Advisors’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,466
Closed -$10K – 15925
2022
Q3 		$10K Sell
1,466
-1,328
-48% -$16K ﹤0.01% 12292
2022
Q2 		$30K Buy
+2,794
New +$38.6K ﹤0.01% 12234
2022
Q1 		– Sell
-559
Closed -$16K – 15086
2021
Q4 		$16K Sell
559
-2,048
-79% -$89.3K ﹤0.01% 13622
2021
Q3 		$170K Buy
2,607
+65
+3% +$4.01K ﹤0.01% 12208
2021
Q2 		$203K Buy
+2,542
New +$212K ﹤0.01% 12130
2020
Q2 		– Sell
-391
Closed -$31K – 10741
2020
Q1 		$31K Buy
+391
New +$63.7K ﹤0.01% 9188

Other funds holding ELOX

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's ELOX Position: Q4 2022 in Review

Citadel Advisors sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q4 2022, closing a stake of 1,466 shares — an estimated $10K sold.

Citadel Advisors first reported a position in ELOX in Q1 2020 and held it in 6 quarters. The position peaked at $203K in Q2 2021. 19 funds tracked by Wall St. Rank hold ELOX as of Q4 2022.

  • Citadel Advisors reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 1,466 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $10K.
  • Citadel Advisors first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
  • Citadel Advisors's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $203K in Q2 2021.
  • 19 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.